Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Combined Febuxostat and Inosine Therapy in Parkinson's Disease
jRCT2041250029Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of febuxostat and inosine in Parkinson's disease (PD) (4 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Change in plasma hypoxanthine from baseline to 12 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
febuxostatinosine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2041250029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250029.